Head-to-head · Value Score
bmiMD vs Remi Meds
Two GLP-1 deals, scored on the same six factors. bmiMD lands a Value Score of 89, Remi Meds a 63. Here's who gives you the honest lower price — and where each one bites back.
bmiMD
#11 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameRemi Meds
#339 · Grade C · Watch List
Est. first month
From $249/mo (0.25 mg dose, compounded)
Save ~82% vs brand-nameThe verdict
bmiMD takes it on Value Score, 89 to 63 — an est. $99/mo first month, with no teaser step-up baked in. Remi Meds isn't out of it: Shoppers who want per-dose-tier compounded GLP-1 with named Strive Pharmacy partner.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | bmiMD | Remi Meds |
|---|---|---|
| Value Score | 89 (A) | 63 (C) |
| Est. first month | $99/mo | From $249/mo (0.25 mg dose, compounded) |
| Save vs brand-name | ~93% | ~82% |
| Semaglutide | $99/mo | From $249/mo (0.25 mg dose, compounded) |
| Tirzepatide | $139/mo | From $349/mo (2.25 mg dose, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
bmiMD
Sub-$100 semaglutide and a low $139 tirzepatide, flat and nationwide — a straight-up low-price play.
Why it's a deal
- $99 flat semaglutide and a low $139 tirzepatide
- Available in all 50 states
- Both molecules priced up front
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Thin public track record; no oral or brand-name option
Remi Meds
Remi Meds is a DTC compounded-GLP-1 telehealth platform offering per-dose-tier compounded semaglutide and tirzepatide-with-B12, plus NAD+, Sermorelin, and Glutathione add-ons.
Why it's a deal
- Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
- LegitScript verification badge on the homepage
- Publishes 503A FDCA compliance language on the tirzepatide page
- Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
- Operating corporate entity disclosed (T-C Health Co)
The fine print
- No named medical director, founder, or physician on any public page
- States served not listed — 'nationwide' claim with no per-state detail
- Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
- Year founded and corporate history are opaque
- Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores bmiMD is ranked on the bmiMD alternatives board, and the same list for the other side is on alternatives to Remi Meds.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.